All Episodes

April 8, 2025 16 mins

Are ADHD medications safe in the long run? Do they affect your heart, your cognition, or even your lifespan? In this evidence-packed episode, we break down the latest peer-reviewed research (2022–2024) to uncover the truth about the long-term effects of ADHD medications—especially stimulant drugs like methylphenidate and lisdexamfetamine.

We’ll explore:

  • 🔍 How ADHD is diagnosed across age groups, and why family medicine clinics are stepping up to meet adult ADHD needs

  • 💔 The cardiovascular risks associated with prolonged stimulant use—including increased rates of hypertension and arterial disease

  • 🧠 Whether stimulants have any lasting impact on ADHD symptoms, cognition, or emotional functioning after discontinuation

  • 📉 The striking reduction in life expectancy for adults with ADHD and what’s driving it

  • 📈 ADHD prescribing trends and regional disparities in the UK

  • 👶 How prenatal exposure to glucocorticoids may increase the risk of ADHD in offspring

  • 📏 The long-term safety of methylphenidate in children, including subtle effects on growth

This episode is your concise, clinically-informed briefing on ADHD medication safety—essential for clinicians, caregivers, patients, and anyone seeking clarity in a sea of opinions.

Sources

📌 Don’t forget to subscribe, share, and leave a review to help others find evidence-based health insights.


Mark as Played

Advertise With Us

Popular Podcasts

24/7 News: The Latest
Therapy Gecko

Therapy Gecko

An unlicensed lizard psychologist travels the universe talking to strangers about absolutely nothing. TO CALL THE GECKO: follow me on https://www.twitch.tv/lyleforever to get a notification for when I am taking calls. I am usually live Mondays, Wednesdays, and Fridays but lately a lot of other times too. I am a gecko.

The Joe Rogan Experience

The Joe Rogan Experience

The official podcast of comedian Joe Rogan.

Music, radio and podcasts, all free. Listen online or download the iHeart App.

Connect

© 2025 iHeartMedia, Inc.